Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Fluoxetine-Safety-Postpartum vs TIGLUTIK KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Glutamate antagonist that inhibits presynaptic glutamate release via sodium channel blockade and modulation of excitatory amino acid transport.
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder,Premenstrual dysphoric disorder (off-label),Bipolar depression (off-label),Social anxiety disorder (off-label)
Amyotrophic lateral sclerosis (ALS)
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
50 mg orally every 12 hours, administered via enteral tube (e.g., nasogastric tube) as a suspension after mixing contents of the 5 mg/m L oral suspension packet with 10 m L of water.
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
Terminal elimination half-life is approximately 9-15 hours, with a mean of 12 hours. Steady-state is reached within 5-7 days. Clinically, this supports twice-daily dosing.
Hepatic via CYP2D6, CYP2C9, CYP3A4; active metabolite norfluoxetine.
Hepatic metabolism primarily via CYP1A2, with minor contributions from CYP3A4 and glucuronidation.
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
Riluzole is primarily eliminated via hepatic metabolism, with <10% excreted unchanged in urine. Metabolites are eliminated renally (~85%) and fecally (~5%).
94% bound to albumin and alpha-1-acid glycoprotein
97% bound primarily to plasma proteins, including albumin and lipoproteins.
12-43 L/kg; extensive tissue distribution including brain, breast milk.
Approximately 3.4 L/kg, indicating extensive tissue distribution, particularly into the CNS.
Oral: 95% (72% after first-pass); food may slightly decrease rate but not extent.
Oral bioavailability is approximately 60% (range 36-76%) due to extensive first-pass metabolism. High-fat meals reduce AUC by 20% and Cmax by 45%.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use cautiously with a maximum dose of 40 mg/day.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh Class A: 20 mg every other day; Class B: 20 mg every third day; Class C: avoid use or use 10 mg every third day with careful monitoring.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B), but use with caution.
Children (8-12 years): 10-20 mg orally once daily; adolescents (13-17 years): 20 mg orally once daily. Maximum 60 mg/day. Weight-based: 0.5-1.0 mg/kg/day, titrate to maximum 1.5 mg/kg/day.
Not approved for pediatric patients under 18 years of age. Safety and efficacy have not been established.
Initial dose 10 mg orally once daily; titrate slowly to a maximum of 40 mg/day due to increased half-life and risk of hyponatremia and QT prolongation.
No specific dose adjustment recommended based on age alone; consider renal function and overall frailty. Monitor for adverse effects, particularly falls and dysphagia.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Serotonin syndrome; risk of bleeding; activation of mania/hypomania; hyponatremia; discontinuation syndrome; QT prolongation (overdose).
Hepatic injury (elevated transaminases, bilirubin),Neutropenia,Interstitial lung disease,Dizziness and somnolence
Concurrent use with MAOIs (or within 14 days); concurrent use with thioridazine or pimozide; known hypersensitivity to fluoxetine.
Hypersensitivity to riluzole or any component of the formulation,Concomitant use with tizanidine,Severe hepatic impairment (Child-Pugh class C)
No specific food interactions; avoid grapefruit juice as it may increase fluoxetine levels. Take with or without food; if GI upset occurs, take with food.
Avoid high-fat meals (e.g., fried foods, cheese, creamy sauces) within 1 hour before or 2 hours after dosing, as they increase absorption and may increase risk of side effects. Grapefruit juice may increase riluzole levels; avoid concurrent consumption.
First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/third trimester: Persistent pulmonary hypertension of the newborn (PPHN) risk ~1.5-2 times baseline; risk of preterm birth and low birth weight. Late third trimester: Risk of poor neonatal adaptation syndrome (PNAS) including jitteriness, respiratory distress, feeding difficulties, and irritability.
FDA Pregnancy Category C. Animal studies show fetal harm at 0.6 times human dose; no adequate human studies. First trimester: potential organogenesis disruption; use only if benefit justifies risk. Second/third trimesters: possible fetal growth restriction; avoid if possible.
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk; M/P ratio ~0.3-1.0 for fluoxetine and ~0.5-2.0 for norfluoxetine. Relative infant dose approximately 2-12% of maternal weight-adjusted dose. Cases of colic, irritability, and poor feeding in breastfed infants have been reported. Generally considered compatible with breastfeeding; however, monitor infant for sedation, poor weight gain, and development.
Excretion into human milk unknown; M/P ratio not established. Caution advised; consider discontinuing nursing or drug based on importance to mother.
Pregnancy increases fluoxetine clearance and decreases plasma concentrations, especially in the third trimester. Dose may need to be increased by 20-50% (e.g., from 20 mg to 30-40 mg daily) to maintain therapeutic effect. Consider therapeutic drug monitoring if available. Postpartum, dose should be reduced to pre-pregnancy levels within 48-72 hours due to reversal of pharmacokinetic changes.
No standard dose adjustments established; pharmacokinetics in pregnancy not studied; monitor clinical response and adjust based on tolerability.
Fluoxetine has a long half-life (4-6 days, norfluoxetine 4-16 days) resulting in steady-state after 2-4 weeks; use lower starting doses (10 mg daily) in postpartum women to minimize side effects; monitor for neonatal adaptation syndrome if used in third trimester; consider dose adjustment in hepatic impairment; avoid in breastfeeding unless benefit outweighs risk due to presence in breast milk.
Tiglutik (riluzole) is the first liquid formulation of riluzole, approved for ALS. It can be administered via feeding tube. Monitor liver function tests (ALT, AST) monthly for 3 months, then quarterly. Avoid use in patients with baseline transaminase elevations >3x ULN. Concomitant use with hepatotoxic drugs (e.g., NSAIDs, acetaminophen >3 g/day) requires caution. Has a high fat emulsion suspension; do not dilute.
Take fluoxetine exactly as prescribed, typically once daily in the morning.,It may take 4 weeks or longer to feel full benefit; do not stop abruptly.,Common side effects include nausea, headache, insomnia, and sexual dysfunction.,Contact your doctor if you experience rash, unusual bleeding, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not breastfeed without discussing risks with your healthcare provider.
Take each dose at least 1 hour before or 2 hours after a meal to avoid food interactions.,Shake the bottle well for at least 30 seconds before each use.,Use the provided dosing syringe to measure the correct dose; do not use household spoons.,If you miss a dose, take it as soon as you remember unless it is close to the next dose; do not double-dose.,Report any yellowing of skin or eyes, dark urine, or abdominal pain immediately as signs of liver toxicity.,You may feel dizzy or lightheaded; avoid driving until you know how the drug affects you.
"Pazopanib, a tyrosine kinase inhibitor, inhibits CYP2D6 activity, leading to reduced metabolism of fluoxetine, a substrate of CYP2D6. This results in increased serum concentrations of fluoxetine and its active metabolite norfluoxetine, elevating the risk of serotonin-related adverse effects such as serotonin syndrome, nausea, and insomnia. The interaction is clinically significant and may require dose adjustment of fluoxetine."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"Concomitant use of tolcapone, a catechol-O-methyltransferase (COMT) inhibitor used in Parkinson's disease, with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), may potentiate serotonergic effects leading to serotonin syndrome, characterized by autonomic instability, neuromuscular hyperactivity, and altered mental status. Additionally, both drugs undergo hepatic metabolism via CYP450 enzymes, and fluoxetine's inhibition of CYP2C9 and CYP3A4 may reduce tolcapone clearance, increasing the risk of hepatotoxicity and other adverse effects. The combination requires careful monitoring for signs of serotonin toxicity and liver injury."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Fluoxetine-Safety-Postpartum vs TIGLUTIK KIT, answered by our medical review team.
Fluoxetine-Safety-Postpartum is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.. TIGLUTIK KIT is a Amyotrophic Lateral Sclerosis Agent that works by Glutamate antagonist that inhibits presynaptic glutamate release via sodium channel blockade and modulation of excitatory amino acid transport.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Fluoxetine-Safety-Postpartum and TIGLUTIK KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Fluoxetine-Safety-Postpartum is: 20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.. The standard adult dose of TIGLUTIK KIT is: 50 mg orally every 12 hours, administered via enteral tube (e.g., nasogastric tube) as a suspension after mixing contents of the 5 mg/m L oral suspension packet with 10 m L of water.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Fluoxetine-Safety-Postpartum and TIGLUTIK KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Fluoxetine-Safety-Postpartum is classified as Category A/B. First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/. TIGLUTIK KIT is classified as Category C. FDA Pregnancy Category C. Animal studies show fetal harm at 0.6 times human dose; no adequate human studies. First trimester: potential organogenesis disruption; use only if benefi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.